Unique keratinocyte-specific effects of interferon-γ that protect skin from viruses, identified using transcriptional profiling

Antiviral Therapy

Volumn 8, Issue 6, 2003, Pages 541-554

  Banno, Tomohiro ^a,b   Adachi, Makoto ^a,c   Mukkamala, Lakshmi ^a   Blumenberg, Miroslav ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DNA; GAMMA INTERFERON;

ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ARTICLE; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DESMOSOME; DNA MICROARRAY; DNA REPLICATION; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; KERATINOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; SKIN CANCER; SKIN PROTECTION; TIGHT JUNCTION; VERRUCA VULGARIS; VIRUS; VIRUS ENVELOPE;

ANTIVIRAL AGENTS; CELL CYCLE; CELL DIFFERENTIATION; CELLS, CULTURED; DNA REPLICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; KERATINOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, VIRAL; SIGNAL TRANSDUCTION; SKIN;

EID: 0346963108     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Isaacs A. Virus Interference. I. The interferon. Proceedings of the Royal Society of London 1957; 147:258-267.
2. Nagano YYK. Inhibiton de l'infection vaccinale par le virus homologue. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 1958; 152:1627-1630.
3. Barber GN. The interferons and cell death: guardians of the cell or accomplices of apoptosis? Seminars in Cancer Biology 2000; 10:103-111.
4. Grander D, Sangfelt O & Erickson S. How does interferon exert its cell growth inhibitory effect? European Journal of Haematology 1997; 59:129-135.
5. Kalvakolanu DV. Interferons and cell growth control. Histology & Histopathology 2000; 15:523-537.
6. Presti RM, Popkin DL, Connick M, Paetzold S & Virgin HW. Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages. Journal of Experimental Medicine 2001; 193:483-496.
7. Tossing G. New developments in interferon therapy. European Journal of Medical Research 2001; 6:47-65.
8. Ucar R, Sanwo M, Ucar K & Beall G. Interferons: their role in clinical practice. Annals of Allergy, Asthma & Immunology 1995; 75:377-386.
9. Hurd DS & Conte ET. Practical uses of the interferons in dermatology. International Journal of Dermatology 1998; 37:881-896.
10. Edwards L. The interferons. Dermatologic Clinics 2001; 19:139-146.
11. Samuel CE. Antiviral actions of interferons. Clinical Microbiology Reviews 2001; 14:778-809.
12. Komine M, Freedberg IM & Blumenberg M. Regulation of epidermal expression of keratin K17 in inflammatory skin diseases. Journal of Investigational Dermatology 1996; 107:569-575.
13. Jiang CK, Flanagan S, Ohtsuki M, Shuai K, Freedberg IM & Blumenberg M. Disease-activated transcription factor: allergic reactions in human skin cause nuclear transcription of STAT-91 and induce synthesis of keratin K17. Molecular Cell Biology 1994; 14:4759-4769.
14. Carroll JM, Crompton T, Seery JP & Watt FM. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. Journal of Investigational Dermatology 1997; 108:412-422.
15. Gomi T, Shiohara T, Munakata T, Imanishi K & Nagashima M. Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Archives of Dermatology 1991; 127:827-830.
16. Gottlieb AB. Immunologic mechanisms in psoriasis. Journal of Investigational Dermatology 1990; 95:18S-19S.
17. Castello G, Ruocco V, Satriano RA & Zarrilli D. Role of interferons in the therapy of melanoma. Melanoma Research 1992; 1:311-325.
18. Lens MB & Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. Journal of Clinical Oncology 2002; 20:1818-1825.
19. Knobler R. [Interferon-alpha in cutaneous T-cell lymphoma]. Wiener Medizinische Wochenschrift 1993; 143:435-437.
20. Vittorio CC, Rook AH, French LE, Shapiro M, Lehrer MS & Junkins-Hopkins JM. Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma. BioDrugs 2001; 15:431-437.
21. Buechner SA, Wernli M, Harr T, Hahn S, Itin P & Erb P. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. Journal of Clinical Investigation 1997; 100:2691-2696.
22. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, Tanner DJ, Taylor EL, Smiles KA & Peets EA. Intralesional interferon therapy for basal cell carcinoma. Journal of the American Academy of Dermatology 1990; 23:694-700.
23. Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK & Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. Journal of Clinical Oncology 2002; 20:364-370.
24. Edwards L, Berman B, Rapini RP, Whiting DA, Tyring S, Greenway HT Jr, Eyre SP, Tanner DJ, Taylor EL, Peets E et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Archives of Dermatology 1992; 128:1486-1489.
25. Ward SV & Samuel CE. Regulation of the interferon-inducible PKR kinase gene: the KCS element is a constitutive promoter element that functions in concert with the interferon-stimulated response element. Virology 2002; 296:136-146.
26. Levy D & Darnell JE Jr. Interferon-dependent transcriptional activation: signal transduction without second messenger involvement? New Biologist 1990; 2:923-928.
27. Gil J & Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 2000; 5:107-114.
28. Boehm U, Klamp T, Groot M & Howard JC. Cellular responses to interferon-gamma. Annual Review of Immunology 1997; 15:749-795.
29. Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S & Grander D. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999; 18:2798-2810.
30. Harvat BL & Jetten AM. Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ 1996; 7:289-300.
31. Vivo C, Levy F, Pilatte Y, Fleury-Feith J, Chretien P, Monnet I, Kheuang L & Jaurand MC. Control of cell cycle progression in human mesothelioma cells treated with gamma interferon. Oncogene 2001; 20:1085-1093.
32. Shyu RY, Su HL, Yu JC & Jiang SY. Direct growth suppressive activity of interferon-alpha and -gamma on human gastric cancer cells. Journal of Surgical Oncology 2000; 75:122-130.
33. Burke F, East N, Upton C, Patel K & Balkwill FR. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. European Journal of Cancer 1997; 33:1114-1121.
34. Nickoloff BJ, Basham TY, Merigan TC & Morhenn VB. Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Laboratory Investigation 1984; 51:697-701.
35. Reichel RP, Fitz R, Neumann R, Pohl-Markl H, Pichler E, Hoffer Z & Budiman R. Clinical study with recombinant interferon gamma versus interferon alpha-2c in patients with condylomata acuminata. International Journal of STD & AIDS 1992; 3:350-354.
36. Gangemi JD, Pirisi L, Angell M & Kreider JW. HPV replication in experimental models: effects of interferon. Antiviral Research 1994; 24:175-190.
37. Bach EA, Aguet M & Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annual Review of Immunology 1997; 15:563-591.
38. Schindler C. Cytokines and JAK-STAT signaling. Experimental Cell Research 1999; 253:7-14.
39. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A & Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259:1739-1742.
40. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM & Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-1921.
41. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilcek J, Zinkernagel RM & Aguet M. Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259:1742-1745.
42. Lu B, Ebensperger C, Dembic Z, Wang Y, Kvatyuk M, Lu T, Coffman RL, Pestka S & Rothman PB. Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proceedings of the National Academy of Sciences, USA 1998; 95:8233-8238.
43. Durbin JE, Hackenmiller R, Simon MC & Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443-450.
44. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M & Schreiber RD. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84:431-442.
45. Levy DE & Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine & Growth Factor Reviews 2001; 12:143-156.
46. Yu Z, Manickan E & Rouse BT. Role of interferon-gamma in immunity to herpes simplex virus. Journal of Leukocyte Biology 1996; 60:528-532.
47. Cantin E, Tanamachi B, Openshaw H, Mann J & Clarke K. Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. Journal of Virology 1999; 73:5196-5200.
48. Schiffer R, Baron J, Dagtekin G, Jahnen-Dechent W & Zwadlo-Klarwasser G. Differential regulation of the expression of transporters associated with antigen processing, TAP1 and TAP2, by cytokines and lipopolysaccharide in primary human macrophages. Inflammation Research 2002; 51:403-408.
49. Saiura A, Kohro T, Yamamoto T, Izumi A, Wada Y, Aburatani H, Sugawara Y, Hamakubo T, Taniguchi T, Naito M, Kodama T & Makuuchi M. Detection of an upregulation of a group of chemokine genes in murine cardiac allograft in the absence of interferon-gamma by means of DNA microarray. Transplantation 2002; 73:1480-1486.
50. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH & Williams BR. Functional classification of interferon-stimulated genes identified using microarrays. Journal of Leukocyte Biology 2001; 69:912-920.
51. Shtrichman R & Samuel CE. The role of gamma interferon in antimicrobial immunity. Current Opinion on Microbiology 2001; 4:251-259.
52. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW & Schreiber RD. Biologic consequences of Stat1-independent IFN signaling. Proceedings of the National Academy of Sciences, USA 2001; 98:6680-6685.
53. Aberger F, Costa-Pereira AP, Schlaak JF, Williams TM, O'Shaughnessy RF, Hollaus G, Kerr IM & Frischauf AM. Analysis of gene expression using high-density and IFN-gamma-specific low-density cDNA arrays. Genomics 2001; 77:50-57.
54. Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, Haber DA & Harkin DP. BRCA1 regulates the interferon gamma-mediated apoptotic response. Journal of Biological Chemistry 2002; 277:26225-26232.
55. Patrone L, Damore MA, Lee MB, Malone CS & Wall R. Genes expressed during the IFN gamma-induced maturation of pre-B cells. Molecular Immunology 2002; 38:597-606.
56. Ehrt S, Schnappinger D, Bekiranov S, Drenkow J, Shi S, Gingeras TR, Gaasterland T, Schoolnik G & Nathan C. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. Journal of Experimental Medicine 2001; 194:1123-1140.
57. Satoh J & Kuroda Y. Differing effects of IFN beta vs IFN gamma in MS: gene expression in cultured astrocytes. Neurology 2001; 57:681-685.
58. Cardozo AK, Kruhoffer M, Leeman R, Orntoft T & Eizirik DL. Identification of novel cytokine-induced genes in pancreatic beta-cells by high-density oligonucleotide arrays. Diabetes 2001; 50:909-920.
59. Der SD, Zhou A, Williams BR & Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proceedings of the National Academy of Sciences, USA 1998; 95:15623-15628.
60. Chang EH, Ridge J, Black R, Zou ZQ, Masnyk T, Noguchi P & Harford JB. Interferon-gamma induces altered oncogene expression and terminal differentiation in A431 cells. Proceedings of the Society for Experimental Biology & Medicine 1987; 186:319-326.
61. Ridge J, Muller J, Noguchi P & Chang EH. Dynamics of differentiation in human epidermoid squamous carcinoma cells (A431) with continuous, long-term gamma-IFN treatment. In Vitro Cellular & Developmental Biology 1991; 27A:417-424.
62. Simon M & Green H. Participation of membrane-associated proteins in the formation of the cross-linked envelope of the keratinocyte. Cell 1984; 36:827-834.
63. Mahadevappa M & Warrington JA. A high-density probe array sample preparation method using 10- to 100-fold fewer cells. Nature Biotechnology 1999; 17:1134-1136.
64. Li D, Turi TG, Schuck A, Freedberg IM, Khitrov G & Blumenberg M. Rays and arrays: the transcriptional program in the response of human epidermal keratinocytes to UVB illumination. FASEB Journal 2001; 15:2533-2535.
65. Eisen MB, Spellman PT, Brown PO & Botstein D. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences, USA 1998; 95:14863-14868.
66. Rouillard JM, Herbert CJ & Zuker M. OligoArray: genome-scale oligonucleotide design for microarrays. Bioinformatics 2002; 18:486-487.
67. Milisavljevic V, Freedberg IM & Blumenberg M. Characterization of nuclear protein binding sites in the promoter of keratin K17 gene. DNA & Cell Biology 1996; 15:65-74.
68. Mancek M, Pristovsek P & Jerala R. Identification of LPS-binding peptide fragment of MD-2, a toll-receptor accessory protein. Biochemical & Biophysical Research Communications 2002; 292:880-885.
69. Eklund EA & Kakar R. Recruitment of CREB-binding protein by PU.1, IFN-regulatory factor-1, and the IFN consensus sequence-binding protein is necessary for IFN-gamma-induced p67phox and gp91phox expression. Journal of Immunology 1999; 163:6095-6105.
70. Griffiths CE, Voorhees JJ & Nickoloff BJ. Gamma interferon induces different keratinocyte cellular patterns of expression of HLA-DR and DQ and intercellular adhesion molecule-I (ICAM-I) antigens. British Journal of Dermatology 1989; 120:1-8.
71. Dustin ML & Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. Journal of Cell Biology 1988; 107:321-331.
72. Arefieva TL & Krasnikova TL. Monocytic cell adhesion to intact and plasmin-modified fibrinogen: possible involvement of Mac-1 (CD11b/CD18) and ICAM-1 (CD54). Journal of Cell Physiology 2001; 188:403-409.
73. Reano A, Richard MH, Denoroy L, Viac J, Benedetto JP & Schmitt D. Gamma interferon potently induces tryptophanyl-tRNA synthetase expression in human eratinocytes. Journal of Investigative Dermatology 1993; 100:775-779.
74. Saunders N, Dahler A, Jones S, Smith R & Jetten A. Interferon-gamma as a regulator of squamous differentiation. Journal of Dermatological Sciences 1996; 13:98-106.
75. Takahashi H, Asano K, Nakamura S, Ishida-Yamamoto A & Iizuka H. Interferon-γ-dependent stimulation of human involucrin gene expression: STAT1 (signal transduction and activators of transcription 1) protein activates involucrin promoter activity. Biochemistry Journal 1999; 344:797-802.
76. Tamai K, Li K, Silos S, Rudnicka L, Hashimoto T, Nishikawa T & Uitto J. Interferon-gamma-mediated inactivation of transcription of the 230-kDa bullous pemphigoid antigen gene (BPAG1) provides novel insight into keratinocyte differentiation. Journal of Biological Chemistry 1995; 270:392-396.
77. Segre JA, Bauer C & Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nature Genetics 1999; 22:356-360.
78. Brandner JM, Kief S, Grund C, Rendl M, Houdek P, Kuhn C, Tschachler E, Franke WW & Moll I. Organization and formation of the tight junction system in human epidermis and cultured keratinocytes. European Journal of Cell Biology 2002; 81:253-263.
79. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A & Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. Journal of Cell Biology 2002; 156:1099-1111.
80. Samuel CE, Duncan R, Knutson GS & Hershey JW. Mechanism of interferon action. Increased phosphorylation of protein synthesis initiation factor eIF-2 alpha in interferon-treated, reovirus-infected mouse L929 fibroblasts in vitro and in vivo. Journal of Biological Chemistry 1984; 259:13451-13457.
81. Clemens MJ & Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. Journal of Interferon & Cytokine Research 1997; 17:503-524.
82. Nickoloff BJ & Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunology Today 1994; 15:464-469.
83. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T & Taniguchi T. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988; 54:903-913.
84. Taniguchi T, Ogasawara K, Takaoka A & Tanaka N. IRF family of transcription factors as regulators of host defense. Annual Review of Immunology 2001; 19:623-655.